SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
The post SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace.
More From InvestorPlace